Combination MCL-1 inhibitors with anti-cancer agents

A method of treating a TROP-2 expressing cancer comprising:

• administering to a human patient in need a therapeutically effective amount of gemcitabine, and a therapeutically effective amount of an MCL-1 inhibitor;
• wherein the MCL-1 inhibitor is of formula (I):
• or a pharmaceutically acceptable salt thereof;
• wherein R1 is 5-10 membered heteroaryl containing 1-2 heteroatoms;
• wherein each heteroatom is independently selected from nitrogen, sulfur, and oxygen;
• the 5-10 membered heteroaryl of R1 is optionally substituted with 1-3 substituents independently selected from halo, hydroxyl, —CN, C1-6alkyl, C1-6haloalkyl, —ORa, and C3-6cycloalkyl;
• and
• each R2, R3, R4, and R5 is independently hydrogen or C1-6alkyl;
• R6 is hydrogen or halo;
• and
• Ra is independently hydrogen, C1-6alkyl, C2-6alkenyl, and C3-10cycloalkyl.